Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK)
inhibitor that was approved by the FDA for the treatment of renal cell ...
SUTENT® (sunitinib malate) for treatment of advanced renal cell carcinoma,
gastrointestinal stromal tumors & advanced pancreatic NET. Risk info for
Aug 15, 2016 ... Sunitinib: learn about side effects, dosage, special precautions, and more on
Oct 5, 2006 ... This page contains brief information about sunitinib malate and a collection of
links to more information about the use of this drug, research ...
Find out more about sunitinib (also called Sutent®), which may be used to treat a
type of kidney cancer called renal cell carcinoma (RCC), gastrointestinal ...
Easy to read patient leaflet for sunitinib. Includes indications, proper use, special
instructions, precautions, and possible side effects.
Learn about Sutent (Sunitinib Malate) may treat, uses, dosage, side effects, drug
interactions, warnings, patient labeling, reviews, and related medications.
May 16, 2007 ... Sunitinib is metabolized primarily by the cytochrome P450 enzyme, CYP3A4, to
produce its primary active metabolite, which is further ...
Find patient medical information for sunitinib oral on WebMD including its uses,
side effects and safety, interactions, pictures, warnings and user ratings.
Jan 13, 2016 ... Sunitinib (Sutent®) is an oral multikinase inhibitor used in the treatment of some
types of gastrointestinal stromal tumors, renal cell cancers and ...